INTRODUCTION: Stereotactic body radiotherapy (SBRT) is rapidly gaining favor as a new treatment modality for malignant @entity96 . Most of the studies have recruited @entity1 with disseminated disease originating from the liver. This study focuses on disease limited to the liver. AIM: To perform a retrospective analysis of all @entity1 with @entity96 treated by robotic stereotactic body radiation therapy in a single center. MATERIAL AND METHODS: The study included 13 @entity1 with 22 lesions. The inclusion criteria were: @entity1 with 1-4 inoperable @entity409 and absence of any @entity6687 . All but 3 @entity1 received 3 fractions delivered by the Cyberknife system of a total of 45 grey (Gy). The other 3 @entity1 received 30 Gy. RESULTS: The median follow-up time was 10.8 months (range: 7-16). The median dose was 41.5 Gy (range: 30-45). One lesion regressed (8%). In 5 @entity1 , the disease was locally stabilized (38%), and in 7 other @entity1 progression occurred (54%). Twelve @entity1 (92%) are still alive, and 1 @entity1 (8%) died. In 1 @entity1 a new @entity5 ( @entity1778 ) was diagnosed. CONCLUSIONS: The SBRT is well tolerated and effective for local control of most @entity96 . It appears that SBRT is best suited for those @entity1 in whom systemic recurrence can be controlled by chemotherapy. Further studies are mandatory to elucidate these effects on @entity5 of varying histology and to elaborate upon criteria used to select @entity1 who can benefit most from this treatment.

Robotic stereotactic body radiation therapy for liver-limited XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumors', 'liver malignant tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver lesions'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity6687 :: ('MESH:D001651', 'Disease') :: ['extrahepatic disease']
@entity5 :: (MESH:D009369,Disease) :: ['malignant tumors']
